Essential Pharma Acquires Yorkdale Pharma from Rosemont; Sells Oral Liquid Portfolio to Rosemont and Buys Two Product Rights from Novartis
December 21, 2021
Gyrus Capital‑backed Essential Pharma completed a refinancing and executed a series of portfolio transactions in December 2021. Essential Pharma acquired Yorkdale Pharma Limited from Rosemont Pharmaceuticals, divested its 14‑product oral liquid portfolio (Essential Pharma Liquids Limited) to Rosemont, and also acquired worldwide (ex‑US, ex‑India) rights to two products from Novartis to expand its global specialty pharmaceutical portfolio.
- Buyers
- Essential Pharma, Rosemont Pharmaceuticals Limited
- Targets
- Yorkdale Pharma Limited, Essential Pharma Liquids Limited, Two product rights from Novartis (ocular and postpartum therapies)
- Sellers
- Rosemont Pharmaceuticals Limited, Essential Pharma, Novartis
- Industry
- Pharmaceuticals
- Location
- United Kingdom
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.